方法：回顾性分析2012-01/12我院收治的MGD患者52例100眼的临床资料，根据临床表现及体征确诊为MGD，随机分为两组，A组(物理治疗组)26例50眼患者给予局部清洗、热敷、睑板腺开口挑排、妥布霉素地塞米松眼膏及人工泪液等综合治疗，B组(对照组)26例50眼患者仅用人工泪液和妥布霉素地塞米松眼膏药物治疗，比较两组治疗前后患者自觉症状、角膜荧光素染色(FL)、泪液分泌和泪膜破裂时间。

结果：A组自觉症状好转24例47眼，好转率94%，B组自觉症状好转14例27眼，好转率54%，两组间差异有统计学意义(P<0.01)； 两组间泪液分泌治疗后无明显统计学差异(P>0.05)； 泪膜破裂时间(BUT)A组治疗后明显好转，治疗后2，4wk两组间比较有统计学意义(P<0.01)； 角膜荧光素染色(FL)，治疗后2，4wk两组之间有统计学意义(P<0.05)。

结论：MGD是一种可致眼表炎症及损伤的慢性疾病，睑板腺开口挑排等物理治疗睑板腺功能障碍疗效确切，患者满意度高。

METHODS: The MGD 52 patients(100 eyes)admitted to hospital from January 2012 to December 2012 were retrospective analyzed. They were divided into 2 groups. Group A of 26 patients(50 eyes)were treated with local cleaning, heating, opening pick a row, TobraDex-ointment and artificial tears comprehensive treatments. Group B of 26 cases(50 eyes)were only treated with artificial tears and TobraDex-ointment drug treatment. Subjective symptom, corneal fluorescein staining(FL), tear secretion and tear film break-up time(BUT)of the 2 groups before and after treatment were compared.

RESULTS: Symptoms of group A were improved in 24 cases(47 eyes), improvement rate was 94%; group B symptoms improved in 14 cases(27 eyes), improvement rate was 54%, the difference between the two groups was statistically significant(P<0.01). Two sets of tear secretion before and after treatment had no significant difference(P>0.05), tear film BUT in group A was significantly improved after treatment, the differences was statistically significant(P<0.01)between before and after treatment; corneal fluorescein staining(FL )before and after treatment between the two groups has statistically significance(P<0.05).

CONCLUSION: MGD is a chronic disease that can cause ocular inflammation and injury, meibomian gland opening pick row physiotherapy for meibomian gland dysfunction is efficacy and has high patient satisfaction.